Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLIDE Regimen and ASCT for Extranodal NK/T-cell Lymphoma
NCT03154918Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, pegaspargase, ifosfamide, dexamethasone and etoposide in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Sichuan University. Primary endpoints: Progression-Free Survival at 2 years, Overall Response Rate and 1 more. Status: unknown.
02
Drugs
gemcitabinepegaspargaseifosfamidedexamethasoneetoposide
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT03154918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154918.